The SNP Consortium collaboration of 10 pharmaceutical companies and the Wellcome Trust will spend $45 million over two years to identify and map about 300,000 randomly generated SNPs.

The industry partners are AstraZeneca (London); Bayer (Pittsburgh, Pa.); Bristol-Myers Squibb Co. (New York); F. Hoffmann-LaRoche (Nutley, N.J.); Glaxo Wellcome (Research Triangle Park, N.C.); Hoechst Marion Roussel (Kansas City, Mo.); Novartis (Basel, Switzerland); Pfizer (New York); Searle (Skokie, Ill.); and SmithKline Beecham (Philadelphia).

The academic partners are Cold Spring Harbor Laboratory (Cold Spring Harbor, N.Y.); Stanford Human Genome Center (Palo Alto, Calif.); Washington University School of Medicine (St. Louis); the Wellcome Trust's Sanger Centre (Cambridge, U.K.); and the Whitehead Institute for Biomedical Research (Cambridge, Mass.).

Much of the actual SNP discovery is being done at academic genome centers, including the Whitehead Institute, Washington University, and the Sanger Centre in Cambridge, England. Scientists at Stanford University and the Sanger Centre are doing...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?